However, it is important to note that in our study, the association of NAFLD and clinically significant fibrosis with worsening of glycaemic control remained statistically significant even after adjusting for some important confounding factors at baseline, including the use of GLP-1 receptor agonists, SGLT-2 inhibitors or pioglitazone that may positively affect NAFLD (steatosis) and liver fibrosis. The gene discussed is SLC5A2; the disease is Hepatic fibrosis.